Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
about
Cancer genome landscapesOne-Carbon Metabolism in Prostate Cancer: The Role of Androgen SignalingThe Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal CancerThe value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancersSerrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapyAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraSomatic DNA mutation analysis in targeted therapy of solid tumoursBRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapiesBRAF Mutation in Colorectal Cancer: An UpdateToward a Molecular Classification of Colorectal Cancer: The Role of BRAFTime to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinomaMolecular alterations and biomarkers in colorectal cancerMolecular Technologies in the Clinical Diagnostic LaboratoryThe next steps in next-gen sequencing of cancer genomesPrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesDual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancerDiscovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.Beyond RAS and BRAF: a target rich disease that is ripe for pickingRAS and BRAF in metastatic colorectal cancer managementMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerNegative feedback regulation of the ERK1/2 MAPK pathwayPrioritizing therapeutic targets using patient-derived xenograft modelsPI3K and cancer: lessons, challenges and opportunitiesTranslating genomic profiling to gastrointestinal cancer treatment.A spatial simulation approach to account for protein structure when identifying non-random somatic mutationsBRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Genomic sequencing: assessing the health care system, policy, and big-data implications.Resistance to Raf inhibition in cancer.Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model.Change or die: targeting adaptive signaling to kinase inhibition in cancer cells.Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines.Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.The MAPK pathway across different malignancies: a new perspective.Effects of BRAF mutations and BRAF inhibition on immune responses to melanomaBiology of colorectal cancer.Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.
P2860
Q22242276-5E28A96E-2781-441F-BE57-89DA5BC022DDQ26740548-5CCA4035-7D2D-4EDB-8CE4-AF323D8BDDE8Q26744721-78745D59-EBCF-4D5A-9F42-65162B937FADQ26747403-A4FAA02F-DD08-40CC-B63B-17A22004F499Q26751035-D056DA3C-A9F7-40EC-9B87-E2E298E87861Q26751344-5D11A044-0ECD-474E-8BF3-B22907459D8CQ26770324-E47EE497-4CC1-42B1-8894-1C6064C7D2B4Q26772276-50306DD3-5F89-45E1-8ED3-B61C648A6275Q26781926-F0367AD5-0F73-421A-9C3B-4CFF49A16C77Q26827212-26C39DF6-C5A2-46E6-A678-1E695CB1B1ECQ26853261-2EA48F16-64EB-4042-97E7-9A6E5550D5D6Q26862317-3C55D330-28E1-4DEE-960F-0571A08D575FQ26996463-3B04F4D7-71AB-4C8A-B351-91A15AA45D2DQ26998894-C9BF5B5B-8C2D-40DD-B246-BA1F477FB045Q27015224-2F5F60E4-AA7F-4076-B393-08508FAC2509Q27324821-838CD6F3-E4B7-4B4D-BBC7-8150C9B5FA97Q27711042-46EB0B36-FE53-43C5-8436-31D6FB4CAA32Q27852136-FC037770-10E6-44FE-B3CD-5A0B533B5385Q27853105-229F777F-A827-414D-A294-C5AC9B4A5935Q27853216-2383EF61-7604-4B89-B111-9F8C5D87B605Q27853224-418BE321-E8F2-4EB3-BD05-55E438D22128Q28066095-C692792D-69BF-4533-A806-5E79B398D466Q28074175-F27513FE-29EE-4C27-B69D-422F483B43A6Q28076490-3BC30E86-EA1A-4CAD-A85B-813F8750207CQ28079202-9DF2EA76-4E7D-4614-8CA3-A25378A7D935Q28083993-3CB05DB0-5914-48C3-BA1B-DFB300C63F8AQ30080017-ED84E4BC-82E8-41DE-9E37-C8FB69E9AE03Q30239109-16608882-AA68-4B18-9994-99F4DCA5D71FQ30364303-A203942E-96BF-496D-B744-D2058254BC5FQ30458424-E6F20084-D7B4-4B0B-A264-C4524A2D3905Q30835712-665322BE-CF0E-4F06-8768-8FBD3D4A5B72Q33651779-ADE7F577-7285-4C9E-9AD5-66BE2C96B28CQ33767369-0F0058FB-536D-46B1-BEF9-735DB17EBB6DQ34225871-D9B46BBF-A531-428B-9B2B-5ECE0CC6B7A6Q34278085-E73F25FD-181C-4532-A334-2FB14597116CQ34341465-58B2575D-EBE7-4A32-8EC6-BE5CD5DFCA76Q34459097-B0D29FC1-ED3C-471A-99C0-0858B4C94276Q34646279-8BCD3CBB-04AC-4ADE-8100-4F364AB5E34DQ34669618-49C17D5B-60F5-45D6-A7F7-89296CDECBBEQ35033377-5F0163A0-20B8-49D5-9B63-44D62DEA1090
P2860
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Resistance to BRAF inhibition ...... ition or demethylating agents.
@en
Resistance to BRAF inhibition ...... ition or demethylating agents.
@nl
type
label
Resistance to BRAF inhibition ...... ition or demethylating agents.
@en
Resistance to BRAF inhibition ...... ition or demethylating agents.
@nl
prefLabel
Resistance to BRAF inhibition ...... ition or demethylating agents.
@en
Resistance to BRAF inhibition ...... ition or demethylating agents.
@nl
P2093
P2860
P50
P1476
Resistance to BRAF inhibition ...... ition or demethylating agents.
@en
P2093
Chun C Tsao
Farshid Dayyani
Gary E Gallick
Gordon B Mills
Jayesh Desai
John M Mariadason
Michael A Davies
Muling Mao
Robert Lemos
P2860
P304
P356
10.1158/1078-0432.CCR-11-1446
P407
P577
2012-12-18T00:00:00Z